EUVIMEDEUVIMED entdecken
Open Access · CC0

Wilms’ tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP

Ayana E Morales iD, Ruby Gumenick, Caitlyn M Genovese, Yun Yeong Jang, Ariene Ouedraogo, Maite Ibáñez de Garayo, Tania Pannellini, Sanjay Patel, Matthew E Bott, Julio Alvarez, Sung Soo Mun, Jennifer Totonchy und 17 weitere

PLOS Pathogens · 2024

DOI: 10.1371/journal.ppat.1011881 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Ayana E Morales und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Weill Cornell Medicine, New York, New York, United States of America. Hauptthemen laut MEDLINE: Sarcoma, Kaposi, Herpesvirus 8, Human, HIV Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In people living with HIV, Kaposi Sarcoma (KS), a vascular neoplasm caused by KS herpesvirus (KSHV/HHV-8), remains one of the most common malignancies worldwide. Individuals living with HIV, receiving otherwise effective antiretroviral therapy, may present with extensive disease requiring chemotherapy. Hence, new therapeutic approaches are needed. The Wilms’ tumor 1 (WT1) protein is overexpressed and associated with poor prognosis in several hematologic and solid malignancies and has shown promise as an immunotherapeutic target. We found that WT1 was overexpressed in >90% of a total 333 KS biopsies, as determined by immunohistochemistry and image analysis. Our largest cohort from ACTG, consisting of 294 cases was further analyzed demonstrating higher WT1 expression was associated with more advanced histopathologic subtypes. There was a positive correlation between the proportion of infected cells within KS tissues, assessed by expression of the KSHV-encoded latency-associated nuclear antigen (LANA), and WT1 positivity. Areas with high WT1 expression showed sparse T-cell infiltrates, consistent with an immune evasive tumor microenvironment. We show that major oncogenic isoforms of WT1 are overexpressed in primary KS tissue and observed WT1 upregulation upon de novo infection of endothelial cells with KSHV. KSHV latent viral FLICE-inhibitory protein (vFLIP) upregulated total and major isoforms of WT1, but upregulation was not seen after expression of mutant vFLIP that is unable to bind IKKƴ and induce NFκB. siRNA targeting of WT1 in latent KSHV infection resulted in decreased total cell number and pAKT, BCL2 and LANA protein expression. Finally, we show that ESK-1, a T cell receptor–like monoclonal antibody that recognizes WT1 peptides presented on MHC HLA-A0201, demonstrates increased binding to endothelial cells after KSHV infection or induction of vFLIP expression. We propose that oncogenic isoforms of WT1 are upregulated by KSHV to promote tumorigenesis and immunotherapy directed against WT1 may be an approach for KS treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, KaposiHerpesvirus 8, HumanHIV InfectionsHumansCASP8 and FADD-Like Apoptosis Regulating ProteinWT1 ProteinsEndothelial CellsProtein IsoformsTumor Microenvironment

Substanzen

CASP8 and FADD-Like Apoptosis Regulating ProteinWT1 ProteinsProtein IsoformsWT1 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Weill Cornell Medicine, New York, New York, United States of America.
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, United States of America.
  • Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
  • School of Pharmacy, Chapman University, Irvine, California, United States of America.
  • Department of Allergy and Immunology, Icahn School of Medicine, New York, New York, United States of America.
  • Cornell University, Ithaca, New York, United States of America.

ORCID-Profile: Ayana E Morales

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • Weill Cornell Medicine
  • National Cancer Institute
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Morales, A. E., Gumenick, R., Genovese, C. M., Jang, Y. Y., Ouedraogo, A., Ibáñez de Garayo, M., Pannellini, T., Patel, S., Bott, M. E., Alvarez, J., Mun, S. S., Totonchy, J., Gautam, A., Delgado de la Mora, J., Chang, S., Wirth, D., Horenstein, M., Dao, T., Scheinberg, D. A., …, & Cesarman, E. (2024). Wilms’ tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011881

Vancouver

Morales AE, Gumenick R, Genovese CM, Jang YY, Ouedraogo A, Ibáñez de Garayo M, et al. Wilms’ tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1011881

BibTeX
@article{Morales2024,
  author = {Morales, Ayana E and Gumenick, Ruby and Genovese, Caitlyn M and Jang, Yun Yeong and Ouedraogo, Ariene and Ibáñez de Garayo, Maite and Pannellini, Tania and Patel, Sanjay and Bott, Matthew E and Alvarez, Julio and Mun, Sung Soo and Totonchy, Jennifer and Gautam, Archana and Delgado de la Mora, Jesus and Chang, Stephanie and Wirth, Dagmar and Horenstein, Marcelo and Dao, Tao and Scheinberg, David A and Rubinstein, Paul G and Semeere, Aggrey and Martin, Jeffrey and Godfrey, Catherine C and Moser, Carlee B and Matining, Roy M and Campbell, Thomas B and Borok, Margaret Z and Krown, Susan E and Cesarman, Ethel},
  title = {Wilms’ tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP},
  journal = {PLOS Pathogens},
  year = {2024},
  doi = {10.1371/journal.ppat.1011881}
}
Kostenlos starten →